Risdiplam

EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear.

Drug facts

Used for: EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

What it is used for

EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. EVRYSDI is a survival of motor neuron 2 (SMN2) splicing modifier indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Risdiplam; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/risdiplam
APA 7th: sofidex. (2026, August 3). Risdiplam. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/risdiplam
AMA 11th: Risdiplam. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/risdiplam

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.